Once-daily ORAL DOSING
Prescription-strength B12 WITHOUT THE NEEDLE

Eligen® Technology uses SNAC (salcaprozate sodium), a carrier that helps chaperone B12 through the gastric lining.

Visit EligenB12.com to learn more
In a clinical trial, B12-DEFICIENT PATIENTS RECEIVED EITHER ELIGEN B12™ OR IM B12, AND BOTH ACHIEVED NORMAL B12 LEVELS (N=48)²³

```
<table>
<thead>
<tr>
<th>STUDY DAYS</th>
<th>Mean B12 levels³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>IM (pg/mL)</td>
</tr>
<tr>
<td>Day 15</td>
<td>4000</td>
</tr>
<tr>
<td>Day 31</td>
<td>3500</td>
</tr>
<tr>
<td>Day 61</td>
<td>3000</td>
</tr>
<tr>
<td>Day 91</td>
<td>2500</td>
</tr>
</tbody>
</table>

Normal Level ≥350 pg/mL
N=48

• All study patients achieved normal B12 levels³
• Eligen B12™ serum B12 levels were normalized from the first day of evaluation (Day 15) and maintained through the end of the study (Day 91)³

Please see full Important Safety Information on pages 9-10, and attached full Prescribing Information on page 11.

THE SCIENCE OF B12 ABSORPTION¹

CARRIES
B12 molecule

CHAPERONES
B12 across the gastric lining

DELIVERS
B12, regardless of intrinsic factor*
MMA levels were compared in Eligen B12™ and IM B12 patients. MMA levels were similarly decreased in both the Eligen B12™ and IM B12 treatment groups. Elevated MMA and homocysteine levels can be early markers for tissue B12 deficiency prior to hematologic manifestations.

Homocysteine levels were compared in Eligen B12™ and IM B12 patients. Homocysteine levels were similarly decreased in both the Eligen B12™ and IM B12 treatment groups. Measuring for elevated MMA and homocysteine levels is a more sensitive way to screen for B12 deficiency.

Please see full Important Safety Information on pages 9-10, and attached full Prescribing Information on page 11.
Eligen B12™ demonstrated more than double the bioavailability of a conventional OTC oral B12 supplement at the same dose in healthy male patients.

**GREATER BIOAVAILABILITY**

Eligen B12™ demonstrated more than double the bioavailability of a conventional OTC oral B12 supplement at the same dose in healthy male patients.

**Mean serum B12 concentration in healthy male patients**

<table>
<thead>
<tr>
<th>TIME (h)</th>
<th>0</th>
<th>5</th>
<th>10</th>
<th>15</th>
<th>20</th>
<th>25</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg Eligen B12™</td>
<td>1000000</td>
<td>100000</td>
<td>10000</td>
<td>1000</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>10 mg Eligen B12™</td>
<td>1000000</td>
<td>100000</td>
<td>10000</td>
<td>1000</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>1 mg IV B12</td>
<td>1000000</td>
<td>100000</td>
<td>10000</td>
<td>1000</td>
<td>100</td>
<td>100</td>
</tr>
</tbody>
</table>

**ELIGEN B12™ DOSING**

Convenient once-daily dosing

Start your patient with 1 Eligen B12™ tablet 1x daily — fasted state, at least 1 hour before a meal, with 50 mL of water.

This regimen may be adapted based on regular laboratory tests, up to a maximum of 2 tablets daily.

No serious adverse events have been reported in any of the clinical studies. There were no changes of clinical significance in any of the safety parameters evaluated.
The pricing structure for Eligen B12™ was created with an eye toward affordability for patients.

PLUS: Patients pay no more than $45 per prescription.§

EMISPHERE IS COMMITTED TO RESPONSIBLE_PRICING

Eligen B12™ is indicated for the dietary management of patients who have a diagnosed vitamin B12 deficiency that cannot be managed by a modification of the normal diet alone. This deficiency can be caused by a range of conditions in which there is an impaired capacity to absorb vitamin B12.

Important Safety Information

Eligen B12™ is contraindicated in patients with hypersensitivity to cobalt, vitamin B12 or any component of Eligen B12™.

Eligen B12™ is contraindicated in patients with hereditary optic nerve atrophy. Do not use in patients with early hereditary optic nerve atrophy (Leber’s disease). Treatment with vitamin B12 has resulted in severe and swift optic atrophy.

Anaphylactic shock and death have been reported after parenteral vitamin B12 administration. No such reactions have been reported during limited clinical trials with Eligen B12™.

Hypokalemia and sudden death may occur in severe megaloblastic anemia treated intensely with vitamin B12. Folic acid is not a substitute for vitamin B12, although it may improve vitamin B12-deficient megaloblastic anemia. Exclusive use of folic acid in treating vitamin B12-deficient megaloblastic anemia could result in progressive and irreversible neurologic damage.

Blunted or impeded therapeutic response to vitamin B12 may be due to such conditions as infection, uremia, use of drugs having bone marrow-suppressant properties (such as chloramphenicol), and concurrent iron or folic acid deficiency.

Indication

Eligen B12™ is indicated for the dietary management of patients who have a diagnosed vitamin B12 deficiency that cannot be managed by a modification of the normal diet alone. This deficiency can be caused by a range of conditions in which there is an impaired capacity to absorb vitamin B12.

Important Safety Information

Eligen B12™ is contraindicated in patients with hypersensitivity to cobalt, vitamin B12 or any component of Eligen B12™.

Eligen B12™ is contraindicated in patients with hereditary optic nerve atrophy. Do not use in patients with early hereditary optic nerve atrophy (Leber’s disease). Treatment with vitamin B12 has resulted in severe and swift optic atrophy.

Anaphylactic shock and death have been reported after parenteral vitamin B12 administration. No such reactions have been reported during limited clinical trials with Eligen B12™.

Hypokalemia and sudden death may occur in severe megaloblastic anemia treated intensely with vitamin B12. Folic acid is not a substitute for vitamin B12, although it may improve vitamin B12-deficient megaloblastic anemia. Exclusive use of folic acid in treating vitamin B12-deficient megaloblastic anemia could result in progressive and irreversible neurologic damage.

Blunted or impeded therapeutic response to vitamin B12 may be due to such conditions as infection, uremia, use of drugs having bone marrow-suppressant properties (such as chloramphenicol), and concurrent iron or folic acid deficiency.

Remind your patients to visit EligenB12.com to download a coupon sheet.

Eligibility Requirements: Eligible patients pay no more than $45 for each 30-day prescription. Maximum benefits may apply. Offer is limited to 1 prescription fill per month. Keep this coupon, which can be used for additional refills. This coupon is not valid for prescription costs that are reimbursed entirely by your insurance plan or if your prescriptions are purchased under any federal or state healthcare program (including, but not limited to Medicare, Medicaid, Medigap, VA, DoD, or TriCare) or any federal or state patient assistance program. Offer not valid for persons under 18 years of age. Offer not valid in the State of Vermont. This offer cannot be combined with any other promotional offer. Emisphere Technologies reserves the right to rescind, revoke or amend this offer without notice, at any time. Offer good only in the USA and Puerto Rico and void where prohibited or otherwise restricted by law. No cash value.

Please see full Important Safety Information on pages 9-10, and attached full Prescribing Information on page 11.

§Eligibility Requirements: Eligible patients pay no more than $45 for each 30-day prescription. Maximum benefits may apply. Offer is limited to 1 prescription fill per month. Keep this coupon, which can be used for additional refills. This coupon is not valid for prescription costs that are reimbursed entirely by your insurance plan or if your prescriptions are purchased under any federal or state healthcare program (including, but not limited to Medicare, Medicaid, Medigap, VA, DoD, or TriCare) or any federal or state patient assistance program. Offer not valid for persons under 18 years of age. Offer not valid in the State of Vermont. This offer cannot be combined with any other promotional offer. Emisphere Technologies reserves the right to rescind, revoke or amend this offer without notice, at any time. Offer good only in the USA and Puerto Rico and void where prohibited or otherwise restricted by law. No cash value.
Vitamin B12 deficiency that is allowed to progress for longer than 3 months may produce permanent degenerative lesions of the spinal cord. Doses of folic acid greater than 0.1 mg per day may result in hematologic remission in patients with vitamin B12 deficiency. Neurologic manifestations will not be prevented with folic acid, if not treated with vitamin B12, irreversible damage will result.

Doses of vitamin B12 exceeding 10 mcg a day may produce hematologic response in patients with folate deficiency. Vitamin B12 is not a substitute for folic acid, and indiscriminate use of vitamin B12 could mask the true diagnosis.

Vitamin B12 deficiency may suppress the sign of polycythemia vera. Treatment with vitamin B12 may unmask this condition.

No specific adverse reactions were identified during the limited studies with Eligen B12™.

It is not known whether vitamin B12 supplementation causes fetal harm or affects reproduction capacity when administered to a pregnant woman.

The safety and efficacy of Eligen B12™ have not been established in patients below the age of 18 years.
REFERENCES

*STUDY DESIGN
A randomized, open-label study. A total of 48 patients were randomized to receive either Eligen B12™ orally or IM B12. Patients in the Eligen B12™ group self-administered one 1000 μg tablet once daily at least 1 hour before their morning meal for 90 days. Patients in the IM injections group received an IM injection of 1000 μg cyanocobalamin administered on study days 1, 3, 7, 10, 14, 21, 30, 60, and 90.

†STUDY DESIGN
A single-dose, open-label, randomized, parallel-group pharmacokinetic (PK) study of 20 healthy male patients aged 18 to 45 years to assess the PK profile and tolerability of a 5-mg dose of Eligen B12™ and a 5-mg dose of a commercial oral immediate release B12 formulation.